Clinical Efficacy and Safety of BIC/TAF/FTC in Elderly HIV‐Infected Individuals in Southwest China: A Retrospective Observation Study
Immunity, Inflammation and Disease · 2025-11 · 13 (11)
DOI: 10.1002/iid3.70264 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Immunity, Inflammation and Disease, online erschienen am 25.11.2025. Verfasst von Shujing Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Infection Department, Guiyang Public Health Clinical Center, Guiyang, Guizhou, China. Hauptthemen laut MEDLINE: HIV Infections, Anti-HIV Agents, Tenofovir, Emtricitabine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Long‐term outcome data from real‐world studies of the bictegravir emtricitabine tenofovir alafenamide fumarate (B/F/TAF) regimen in the treatment of elderly patients with HIV/AIDS are still limited. This study evaluated the real‐world effectiveness and safety of B/F/TAF in elderly HIV‐infected individuals in southwest China.
Methods
This was an observational, single‐center, retrospective study that enrolled antiretroviral therapy (ART)‐naïve ( n = 149) and ART‐experienced ( n = 143) patients with HIV infection between January 2021 and April 2024. The main endpoint was the viral suppression rate of HIV RNA < 50 copies/ml at 48 weeks, and change in CD4 cell count, CD4/CD8 ratio, body weight, blood lipid and safety were secondary endpoints.
Results
The proportions of ART‐naïve and ART‐experienced HIV‐infected cases with VL < 50 copies/mL at 48 weeks were 93.1% and 92.9%, respectively. CD4 cell counts and CD4/CD8 ratios increased significantly from baseline at 48 weeks ( p < 0.001). In the treatment‐naive group, ALT, AST, eGFR, and Glu decreased significantly from baseline at 48 weeks, while body weight, Scr, TC, HDL, and LDL increased significantly. Among patients previously administered ART, eGFR increased significantly from baseline at 48 weeks, while AST, LDL, and Scr decreased significantly; other indicators showed no significant changes from baseline. The incidence rates of adverse events were 11.7% and 4.3% in treatment‐naïve and treatment‐experienced, respectively.
Conclusions
For elderly HIV/AIDS patients, B/F/TAF is a safe option to achieve and maintain virological suppression and immune recovery. In terms of lipid metabolism, the metabolic effects of BIC/FTC/TAF in the treated patients are not significant, and the effects in untreated patients require longer follow‐up.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection Department, Guiyang Public Health Clinical Center, Guiyang, Guizhou, China.
ORCID-Profile: Hai Long
Zitieren
APA
Ma, S., Xie, X., Fu, Y., Gan, L., Yang, X., Wang, Q., & Long, H. (2025). Clinical Efficacy and Safety of BIC/TAF/FTC in Elderly HIV‐Infected Individuals in Southwest China: A Retrospective Observation Study. Immunity, Inflammation and Disease, 13(11). https://doi.org/10.1002/iid3.70264
Vancouver
Ma S, Xie X, Fu Y, Gan L, Yang X, Wang Q, et al. Clinical Efficacy and Safety of BIC/TAF/FTC in Elderly HIV‐Infected Individuals in Southwest China: A Retrospective Observation Study. Immunity, Inflammation and Disease. 2025;13(11). doi:10.1002/iid3.70264
BibTeX
@article{Ma2025,
author = {Ma, Shujing and Xie, Xiaoxin and Fu, Yanhua and Gan, Lin and Yang, Xiaoyan and Wang, Qing and Long, Hai},
title = {Clinical Efficacy and Safety of BIC/TAF/FTC in Elderly HIV‐Infected Individuals in Southwest China: A Retrospective Observation Study},
journal = {Immunity, Inflammation and Disease},
year = {2025},
volume = {13},
number = {11},
doi = {10.1002/iid3.70264}
}
EUVIMED